Introduction {#S0001}
============

The prevalence of thyroid carcinoma accounts for 1% in malignancies. In particular, the subtype of papillary carcinoma with low malignancy and well prognosis is the most common one.[@CIT0001] The incidence of thyroid carcinoma varies a lot in different regions, races and genders. Females are more affected by thyroid carcinoma than males, with the female-male incidence ratio of (2--4): 1.[@CIT0002],[@CIT0003] Thyroid carcinoma occurs in any age, which typically affects young adults.[@CIT0004] It is necessary to clarify the molecular mechanism underlying the occurrence and progression of thyroid carcinoma.

m^6^A methylation is the most abundant mRNA modification in eukaryotes, which is involved in various biological processes, including tissue development, stem cell differentiation, DNA damage repair, etc.[@CIT0005],[@CIT0006] In addition, m^6^A methylation is closely linked to cancer.[@CIT0007] Cancer drugs targeting m^6^A methylation are promising in the clinical application.[@CIT0008],[@CIT0009] Abnormally expressed enzymes involved in m^6^A methylation may result in pathological conditions.[@CIT0010],[@CIT0011] Under the assistance of methyltransferases (ie METTL3, METTL14 and WTAP), methylation modification presents on the N^6^-Methyladenosine.[@CIT0007],[@CIT0012]

RNAs are the core components of the genome and the linkage between genetic information (DNAs) and proteins.[@CIT0013],[@CIT0014] METTL3 is widely expressed and highly conserved in the majority of eukaryotes.[@CIT0015] During the tumor progression, m^6^A methylation exerts a dual role, which could either promote or alleviate the malignant progression.[@CIT0016] It is reported that m^6^A methylation is involved in many types of cancer, and it displays certain diagnostic and therapeutic potentials.[@CIT0017],[@CIT0018]

Transcription factors are protein molecules that can specifically bind to upstream of the 5ʹ end of the gene, thereby ensuring target gene expression with a specific intensity.[@CIT0019] TCF1 is expressed in multiple isoforms. All isoforms of TCF1 share the common HDAC and DNA binding domains.[@CIT0020],[@CIT0021] This study aims to uncover the progression of thyroid carcinoma promoted by the m6A methyltransferase METTL3 through regulating m^6^A methylation on TCF1 mRNA.

Methods {#S0002}
=======

Subjects {#S0002-S2001}
--------

Thyroid carcinoma tissues and paracancerous ones were surgically resected from thyroid carcinoma patients undergoing surgery in Cancer Hospital of the University of Chinese Academy of Sciences. None of the enrolled patients had the medical history of preoperative anti-tumor therapy. Tissue samples were immediately frozen in liquid nitrogen and stored at −80°C. Patients and their families in this study have been fully informed. This study was approved by the Ethics Committee of Cancer Hospital of the University of Chinese Academy of Sciences, and conducted in accordance with the Declaration of Helsinki. All samples received written informed consent from the patients.

Cell Culture {#S0002-S2002}
------------

Normal thyroid cell line (Nthy-ori3-1) and thyroid carcinoma cell lines (TPC-1 and BC-PAP) were purchased from ATCC (Manassas, VA, USA). Cells were cultured in low-glucose Dulbecco's modified eagle medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS) (Gibco, Rockville, MD, USA) and 1% penicillin-streptomycin.

Plasmid Construction and Cell Transfection {#S0002-S2003}
------------------------------------------

TCF1 cDNA was cloned into pcDNA3.0, that was, pcDNA3.0-TCF1. Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at 60% confluence. Fresh medium was replaced 6 hrs later. Transfected cells for 48 h were collected for functional experiments.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#S0002-S2004}
----------------------------------------------------------

TRIzol (Invitrogen, Carlsbad, CA, USA) was applied for isolating cellular RNA, which was quantified using a spectrometer. RNA was reversely transcribed into cDNA using the PrimeScript RT reagent Kit (Takara, Tokyo, Japan). SYBR Premix Ex Taq TM (Takara, Tokyo, Japan) was utilized for qRT-PCR for 35--40 cycles.

Western Blot {#S0002-S2005}
------------

Cellular protein was isolated and electrophoresed. Protein samples were loaded on polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Subsequently, non-specific antigens were blocked in 5% skim milk for 2 hrs. Membranes were reacted with primary and secondary antibodies for the indicated time. Band exposure and analyses were finally conducted.

CCK-8 Assay {#S0002-S2006}
-----------

1×10^3^ cells per well were inoculated in a 96-well plate. After cell culture for 6, 24, 48, 72 and 96 h, 10 μL of CCK-8 reagent was added in each well, respectively. Following 1-h incubation at 37°C, optimal density at 450 nm was measured. Each group had five replicates.

RNA-Binding Protein Immunoprecipitation (RIP) Assay {#S0002-S2007}
---------------------------------------------------

RIP assay was performed following the procedures of Millipore Magna RIP Kit. Cells were incubated with the input, corresponding antibodies or anti--IgG at 4°C overnight. A protein-RNA complex was obtained after capturing intracellular specific proteins by the antibody. Subsequently, proteins were digested by proteinase K to extract RNAs. During the experiment, the magnetic beads were repeatedly washed with RIP washing buffer to remove non-specific adsorption as much as possible. The immunoprecipitant RNAs were finally quantified by qRT-PCR.

Wound Healing Assay {#S0002-S2008}
-------------------

All instruments were required for 30-min ultraviolet radiation, including a ruler, a marker pen and a 200 μL pipette. Five lines with 0.5--1 cm interval were depicted on the back of a 6-well plate using a marker pen. Subsequently, 5×10^5^ cells/well were inoculated in a 6-well plate. An artificial wound was created in the confluent cell monolayer using a 200 μL pipette tip. Wound closure was captured at 0 and 24 h, respectively.

TOP/FOP-Flash Luciferase Reporter Assay {#S0002-S2009}
---------------------------------------

TOP/FOP-Flash luciferase reporter assay was conducted as previously reported.[@CIT0018] Cells were inoculated in a 24-well plate and transfected with TOP/FOP plasmids (Simo Biomedical Technology, Shanghai, China). Cells were then lysed for determining relative luciferase activity.

Statistical Analyses {#S0002-S2010}
--------------------

SPSS 16.0 (SPSS IBM, Armonk, NY USA) was used for all statistical analyses. Data were expressed as mean ± SD. A comparison between multiple groups was done using a one-way ANOVA test, followed by Post Hoc Test (Least Significant Difference). Survival analysis was conducted by Kaplan--Meier method, followed by Log rank test for comparing differences between curves. Pearson analysis was applied for assessing the relationship between expression levels of METTL3 and TCF1 in thyroid carcinoma tissues. *P*\<0.05 indicated the significant difference.

Results {#S0003}
=======

METTL3 and TCF1 Were Upregulated in Thyroid Carcinoma {#S0003-S2001}
-----------------------------------------------------

In thyroid carcinoma tissues (n=48), METTL3 and TCF1 were markedly upregulated than those of paracancerous ones (n=24) ([Figure 1A](#F0001){ref-type="fig"} and C). Kaplan--Meier curves revealed poor survival in thyroid carcinoma patients expressing a high level of METTL3 ([Figure 1B](#F0001){ref-type="fig"}). In addition, expression levels of METTL3 and TCF1 were positively correlated in thyroid carcinoma tissues ([Figure 1D](#F0001){ref-type="fig"}). After analyzing their clinical data, it was found that METTL3 level was correlated to tumor size, TNM staging and lymphatic metastasis rate in thyroid carcinoma patients, while unrelated to age and sex ([Table 1](#T0001){ref-type="table"}). It is suggested that METTL3 and TCF1 were involved in the progression of thyroid carcinoma.Table 1Association of METTL3 Expression with Clinicopathologic Characteristics of Thyroid CarcinomaClinicopathologic FeaturesNumber of CasesMETTL3 Expression*p* valueLow\
(n=24)High\
(n=24)Age (years)0.7711 ≤60271413 \>60211011Gender0.5623 Male221210 Female261214Tumor size0.0093 ≤5CM25178 \>5CM23716TNM stage0.0005 I\~II26197 III\~IV22517Lymph node metastasis0.0088 Absent27189 Present21615 Figure 1METTL3 and TCF1 were upregulated in thyroid carcinoma. (**A**) METTL3 levels in paracancerous tissues and thyroid carcinoma tissues. (**B**) Overall survival in thyroid carcinoma patients expressing a high or low level of METTL3. (**C**) TCF1 levels in paracancerous tissues and thyroid carcinoma tissues. (**D**) A positive correlation between expression levels of METTL3 and TCF1 in thyroid carcinoma tissues. \**P*\<0.05.

Knockdown of METTL3 Suppressed Migratory Ability in Thyroid Carcinoma {#S0003-S2002}
---------------------------------------------------------------------

Consistently, METTL3 was highly expressed in thyroid carcinoma cells than that of normal thyroid cells ([Figure 2A](#F0002){ref-type="fig"}). Transfection efficacy of si-METTL3 was firstly verified in TPC-1 cells ([Figure 2B](#F0002){ref-type="fig"}). As wound healing assay results reflected, migratory ability was remarkably inhibited in TPC-1 cells transfected with si-METTL3 than those of controls ([Figure 2C](#F0002){ref-type="fig"}). Subsequently, we found that transfection of si-METTL3 markedly decreased proliferative ability in TPC-1 cells ([Figure 2D](#F0002){ref-type="fig"}). On the contrary, transfection of pcDNA-METTL3 effectively upregulated METTL3 level in thyroid carcinoma cells ([Figure 2E](#F0002){ref-type="fig"}). Overexpression of METTL3, as expected, enhanced migratory ability ([Figure 2F](#F0002){ref-type="fig"}) and proliferative rate ([Figure 2G](#F0002){ref-type="fig"}) in TPC-1 cells. It is considered that METTL3 aggravated the malignant progression of thyroid carcinoma through stimulating tumor cell metastasis.Figure 2Knockdown of METTL3 suppressed migratory ability in thyroid carcinoma. (**A**) METTL3 levels in Normal thyroid cell line (Nthy-ori3-1) and thyroid carcinoma cell lines (TPC-1 and BC-PAP). (**B**) Transfection efficacy of si-METTL3 in TPC-1 cells. (**C**) Wound healing assay revealed migration in TPC-1 cells transfected with NC or si-METTL3 at 0 and 24 h (magnification: 40×). (**D**) si-METTL3 significantly inhibited proliferation of TPC-1 cells. (**E**) pcDNA-METTL3 effectively upregulated METTL3 level in thyroid carcinoma cells. pcDNA-METTL3 markedly increased migration (**F**) and proliferation (**G**) of TPC-1 cells. \*P\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.

METTL3 Induced m^6^A Methylation on TCF1 mRNA and Thus Upregulated Protein Level of TCF1 {#S0003-S2003}
----------------------------------------------------------------------------------------

Interestingly, transfection of si-METTL3 downregulated protein level of TCF1 in TPC-1 cells ([Figure 3A](#F0003){ref-type="fig"}). Moreover, knockdown of METTL3 decreased TOP/FOP ratio, suggesting the blocked activity of Wnt ([Figure 3B](#F0003){ref-type="fig"}). We, therefore, speculated their potential interaction. As RIP assay illustrated, TCF1 was mainly enriched in anti-METTL3 than that of anti--IgG ([Figure 3C](#F0003){ref-type="fig"}). Protein level of IGF2BP2 was downregulated in TPC-1 cells transfected with si--IGF2BP2 ([Figure 3D](#F0003){ref-type="fig"}). In TPC-1 cells, protein level of TCF1 was downregulated after transfection of si--IGF2BP2 ([Figure 3D](#F0003){ref-type="fig"}). RIP assay further verified the interaction between TCF1 and IGF2BP2 ([Figure 3E](#F0003){ref-type="fig"}). More importantly, knockdown of METTL3 greatly decreased the enrichment abundance of TCF1 in anti--IGF2BP2 ([Figure 3F](#F0003){ref-type="fig"}). The above data demonstrated that METTL3 induced m^6^A methylation on TCF1 mRNA and thus upregulated protein level of TCF1.Figure 3METTL3 induced m^6^A methylation on TCF1 mRNA and thus upregulated protein level of TCF1. (**A**) Protein level of TCF1 in TPC-1 cells transfected with NC or si-METTL3. (**B**) Relative TOP/FOP ratio in TPC-1 cells transfected with NC or si-METTL3. (**C**) Relative enrichment of TCF1 in input, anti-METTL3 and anti--IgG. (**D**) Protein level of TCF1 in TPC-1 cells transfected with NC or si--IGF2BP2. (**E**) Relative enrichment of TCF1 in input, anti--IGF2BP2 and anti--IgG. (**F**) Relative enrichment of TCF1 in input, anti--IGF2BP2 and anti--IgG after transfection of NC or si-METTL3 in TPC-1 cells. \*\**P*\<0.01, \*\*\**P*\<0.001.

METTL3 Activated the Wnt Pathway Through TCF1 {#S0003-S2004}
---------------------------------------------

Since the interaction between METTL3 and TCF1 has been confirmed, we speculated whether TCF1 was involved in the progression of thyroid carcinoma regulated by METTL3. We first tested the transfection efficacy of pcDNA TCF1 by Western blot ([Figure 4A](#F0004){ref-type="fig"}). TOP/FOP-Flash results pointed out that overexpression of TCF1 partially reversed the inhibitory effect of downregulated METTL3 on the activity of Wnt ([Figure 4B](#F0004){ref-type="fig"}). Similarly, the inhibited migratory ability in thyroid carcinoma cells transfected with si-METTL3 was abolished by overexpression of TCF1 ([Figure 4C](#F0004){ref-type="fig"}). Collectively, METTL3 activated the Wnt pathway through m^6^A methylation on TCF1 mRNA, thus aggravating the progression of thyroid carcinoma.Figure 4METTL3 activated the Wnt pathway through TCF1. TPC-1 cells were transfected with NC, si-METTL3 or si-METTL3 + pcDNA TCF1. (**A**) Protein level of TCF1; (**B**) Relative TOP/FOP ratio; (**C**) Migratory ability (magnification: 40×). \*\*P\<0.01, \*\*\**P*\<0.001.

Discussion {#S0004}
==========

Thyroid carcinoma is a highly prevalent endocrine tumor, with the incidence of 7.7/100,000. In recent years, its incidence has been risen globally.[@CIT0022] Thyroid carcinoma has multiple subtypes presenting different clinical and pathological features.[@CIT0023] Target drugs on specific genes related to thyroid carcinoma, including BRAF and RET, contribute to improve the clinical outcome of affected people.[@CIT0024] After active treatment of surgical resection combined radioactive iodine and thyroid hormone suppression therapy, thyroid carcinoma patients usually achieve a satisfied prognosis.[@CIT0025]

Previous studies have shown that RNA methylation accounts for over 60% of all RNA modifications, including m^6^A, m^1^A and m^5^C, etc. Among them, m^6^A is the most popular one.[@CIT0010],[@CIT0026] In eukaryotes, the 5ʹ end cap and the 3ʹ end poly(A) modification exert an important role in transcriptional regulation, while the internal modification of mRNA contributes to maintain mRNA stability.[@CIT0027] Currently, three kinds of enzymes have been identified in m^6^A methylation, including demethylases, methylases and methylation recognition enzymes.[@CIT0028] Among them, m^6^A methyltransferase complex is composed of METTL3, METTL14 and WTAP.[@CIT0029] m^6^A methylation is discovered to affect tumor progression.[@CIT0030] In this paper, METTL3 was found to be upregulated in thyroid carcinoma tissues. METTL3 level predicted a poor prognosis in thyroid carcinoma patients as an oncogene. In vitro experiments further confirmed its promotive effect on migratory ability in thyroid carcinoma cells.

The initiation process of eukaryotic transcription is very complicated and often requires the assistance of various protein factors. A transcription initiation complex formed by transcription factor and RNA polymerase II participates in the process of transcription initiation.[@CIT0031] TCF1 is encoded by the Tcf7 gene, which is the downstream effector of the classical Wnt pathway.[@CIT0032],[@CIT0033] Our analyses showed that TCF1 was upregulated in thyroid carcinoma tissues. Importantly, METTL3 induced m^6^A methylation on TCF1 mRNA, thus aggravating the progression of thyroid carcinoma by activating the Wnt pathway.

Conclusions {#S0005}
===========

Upregulated m6A methyltransferase METTL3 promotes the progression of thyroid carcinoma through m^6^A methylation on TCF1 mRNA.
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